Private equity giant Blackstone Inc. (NYSE:BX) is reportedly close to finalizing a deal to sell Alinamin Pharmaceutical, a Japanese supplement maker, to North Asian buyout fund MBK Partners for 350 billion yen ($2.17 billion). The agreement is anticipated to be finalized shortly, reported Reuters, citing a person familiar with the matter. Also Read: Private Equity Giant Blackstone Targets Japanese Market, Anticipates ‘Accelerated Growth’: Report According to the Nikkei, MBK plans to leverage its ...